Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Daré Bioscience ( (DARE) ) just unveiled an update.
On June 24, 2025, Daré Bioscience received approval from the Nasdaq Hearings Panel for its modified plan to regain compliance with Nasdaq Listing Rules, with a conditional continued listing period until August 12, 2025. The company must demonstrate compliance with either the Stockholders’ Equity Rule or the Minimum MVLS Rule by July 31, 2025, or face potential delisting, which could impact its stock market presence and capital-raising capabilities.
The most recent analyst rating on (DARE) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Daré Bioscience stock, see the DARE Stock Forecast page.
Spark’s Take on DARE Stock
According to Spark, TipRanks’ AI Analyst, DARE is a Neutral.
Daré Bioscience’s overall stock score reflects significant financial distress and technical weakness. Despite strategic initiatives outlined in the earnings call, the company’s negative financial metrics and bearish technical indicators are substantial concerns. Valuation metrics further underscore the risks, with negative earnings and a lack of dividend yield.
To see Spark’s full report on DARE stock, click here.
More about Daré Bioscience
Daré Bioscience, Inc. operates in the biopharmaceutical industry, focusing on developing innovative products for women’s health. The company is known for its efforts in advancing therapies for contraception, fertility, and sexual health, aiming to address unmet needs in the market.
Average Trading Volume: 22,375
Technical Sentiment Signal: Sell
Current Market Cap: $22.66M
For an in-depth examination of DARE stock, go to TipRanks’ Overview page.